Related Experiment Video
Updated: Dec 17, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.9K
Hypertensive Retinopathy Secondary to Anlotinib Treatment
Xiaohua Zhang1, Li Peng1, Qing Xie1
1Department of Ophthalmology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.
Frontiers in Pharmacology
|June 26, 2020
Summary
Anlotinib, an oral cancer drug, can cause hypertensive retinopathy, a condition affecting vision. Patients on Anlotinib require close monitoring for blood pressure and eye complications.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Anlotinib is an oral multi-targeted tyrosine kinase inhibitor used for cancer treatment.
- Hypertensive retinopathy is a serious complication associated with elevated blood pressure.
Observation:
- A middle-aged woman experienced sudden vision loss, headache, nausea, and vomiting after starting Anlotinib.
- Her blood pressure significantly elevated to 167/113 mm Hg.
- Fundus examination revealed optic disc edema, macular exudates, retinal hemorrhages, and cotton-wool spots.
Findings:
- Optical coherence tomography (OCT) showed outer retinal atrophy and hard exudates.
- The patient was diagnosed with hypertensive retinopathy secondary to Anlotinib use.
- Discontinuation of Anlotinib and antihypertensive treatment led to blood pressure normalization and vision recovery.
Implications:
- Anlotinib can induce hypertensive retinopathy, necessitating vigilant monitoring in patients.
- Early detection and management are crucial to prevent irreversible vision loss.
- This case highlights the importance of interdisciplinary care in managing cancer patients with potential drug-induced toxicities.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
366
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
366
01:27Open Angle Glaucoma: Treatment
873
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
873
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.1K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
333
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
333
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.2K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K
01:28Angle Closure Glaucoma: Treatment
1.0K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K